LAVA Therapeutics N.V. (LVTX)
1.740
0.00 (0.00%)
Inactive · Last trade price on Nov 20, 2025

LAVA Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingSep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Revenue
4.9911.986.7719.395.353.75
Revenue Growth
-32.06%77.01%-65.09%262.45%42.78%-
Gross Profit
4.9911.983.2919.395.35-11.95
Operating Income
-21.55-25.79-43.39-34.84-43.61-14.67
Net Income
-23.18-25.11-41.87-31.91-42.36-15.93
Earnings Per Share
-0.86-0.94-1.57-1.23-2.14-39.90
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingSep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Cash & Investments
49.6676.5895.57132.87133.215.82
Total Debt
-5.286.115.454.874.08
Net Cash (Debt)
49.6671.389.46127.42128.3411.74
Net Cash Growth
-31.59%-20.30%-29.79%-0.72%993.54%110.59%
Net Cash Per Share
1.852.663.354.926.5029.40

Cash Flow & CapEx

Fiscal YearTTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingSep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Operating Cash Flow
-30.76-19.54-40.284.04-28.65-9.31
Capital Expenditures
--0.02-0.73-0.59-0.76-0.5
Free Cash Flow
-30.76-19.57-41.013.46-29.41-9.81
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingSep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Gross Margin
100.00%100.00%48.56%100.00%100.00%-
Operating Margin
-431.92%-215.26%-641.07%-179.66%-815.20%-391.59%
Pretax Margin
-450.90%-204.34%-614.77%-163.26%-788.75%-423.91%
Profit Margin
-464.59%-209.60%-618.57%-164.55%-791.68%-425.06%
FCF Margin
-616.35%-163.30%-605.91%17.82%-549.74%-261.78%

Valuation

Fiscal YearCurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingAug '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
P/FCF Ratio
---26.62--
PS Ratio
9.382.096.144.7526.50-